Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China-Biotics continues probiotics growth

This article was originally published in The Tan Sheet

Executive Summary

New retail products sold in the firm's Shining outlets helped drive net sales up 35.5 percent to $15.4 million in the first quarter of fiscal 2010. Shanghai-based China-Biotics reported Aug. 17 that net income for the April-June also rose significantly, to $5.8 million from $3.2 million. Quarterly earnings per share grew to 34 cents from 19 cents, the firm said. Looking ahead, the probiotics manufacturer intends to slow retail expansion as it readies a new facility to begin trial production of bulk additives in its second quarter (1"The Tan Sheet" July 20, 2009). China-Biotics added it applied in July for patents for four probiotics-based yogurt products with China's State Intellectual Property Office and anticipates receiving patent certificates in about two years

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel